Table 1.

Clinical Characteristics of 1-Year Survivors Included in the Study and in the Subgroup for Quality-of-Life Analysis

Characteristic	Entire Study Cohort(N = 1,087)		Subgroup With Patient-Reported Outcomes(n = 544)
	No.	%	No.	%
Age at transplantation, years
Median	53		56
Range	21-78		21-78
Follow-up of patients still alive, months
Median	37		41
Range	12-77		12-77
Race*
White	857	84	441	86
Nonwhite	167	16	72	14
Sex
Male	654	60	326	60
Female	433	40	218	40
Diagnosis
Chronic leukemia	87	8	37	7
Acute leukemia	304	28	147	27
Lymphoma	299	28	155	28
Multiple myeloma	186	17	98	18
Myelodysplastic syndrome	144	14	74	14
Other cancer	15	1	3	1
Nonmalignant disease	52	5	30	6
Disease risk
Early	236	22	117	22
Intermediate	314	29	158	29
Advanced	485	45	239	44
Nonmalignant	52	5	30	6
Transplantation type
Autologous/syngeneic	493	45	259	48
Related donor	264	24	118	22
Unrelated donor	330	30	167	31
Sex match*
Female to male	129	12	58	11
Other sex combinations	461	43	226	42
Autologous/syngeneic	493	46	259	48
Graft source
Peripheral blood	977	90	496	91
Bone marrow	92	8	42	8
Umbilical cord blood	18	2	6	1
Conditioning
High-dose therapy with total body irradiation†	236	22	111	20
High-dose therapy without total body irradiation†	688	63	350	64
Reduced intensity	163	15	83	15
Graft-versus-host disease (allogeneic patients)
Acute grade 2	364	61	176	62
Acute grade 3	46	8	21	7
NIH chronic treated with systemic treatment‡	344	60	179	64

Abbreviation: NIH, National Institutes of Health.

^*Race unknown for 63 patients in overall study cohort and for 31 patients in quality-of-life subgroup; sex match unknown for four patients in overall study cohort and one patient in quality-of-life subgroup.

^†Antithymocyte globulin included in conditioning regimen for 57 patients in overall study cohort and for 32 patients in quality-of-life subgroup.

^‡Cumulative incidence at 5 years.